You are here

Category
Technology Name
Briefcase
Scientist
118
  Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry. Leukotrienes:   Drugs: §  118 - Monoclonal antibody to Buserelin      Description: Rat...

 

Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs

May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry.

Leukotrienes:

 

Drugs:

§  118 - Monoclonal antibody to Buserelin

     Description: Rat monoclonal antibodies raised against Buserelin.

     Available clone: 8B4, IgG1.

 
+
  • Dr. Fortune Kohen
143
Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry. Leukotrienes: Drugs: §  143 - Monoclonal antibody to Medroxy-progesterone-acetate     ...

Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs

May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry.

Leukotrienes:

Drugs:

§  143 - Monoclonal antibody to Medroxy-progesterone-acetate

     Description: Rat monoclonal antibodies raised against Medroxy-progesterone- acetate(MPA)-3-carboxymethyl oxime- BSA. Available clone: 1F5, IgG1.

     Medroxy-progesterone-acetate (MPA) is a highly potent progestational steroid that has been used worldwide as a contraceptive.

+
  • Dr. Fortune Kohen
238
238 - CP Peptide Description: Core peptide (CP; GLRILLLKV-D-stereoisomer), a synthetic peptide coding for the transmembrane domain of the ?-subunit of the T-cell receptor (TCR), a region that has been identified to be crucial for the assembly and function of the TCR. Was shown to significantly inhibit...

238 - CP Peptide

Description: Core peptide (CP; GLRILLLKV-D-stereoisomer), a synthetic peptide coding for the transmembrane domain of the ?-subunit of the T-cell receptor (TCR), a region that has been identified to be crucial for the assembly and function of the TCR.

Was shown to significantly inhibit T-cell-mediated inflammation upon subcutaneously administration in animal models. Has the potential of being used as an alternative therapy for immunosuppression.

Reference: Gerber D, Quintana FJ, Bloch I, Cohen IR, Shai Y. 2005. D-enantiomer peptide of the TCRalpha transmembrane domain inhibits T-cell activation in vitro and in vivo. FASEB J. 19(9):1190-2.

+
  • Prof. Yechiel Shai
295
295 – Milstein catalyst Description: Carbonylhydrido[6-(di-t-butyl-phosphinomethylene)-2-(N,N-diethylaminomethyl)-1,6-dihydropyridine]ruthenium(II). Ruthenium-based catalyst that converts amines and alcohols into amides. Reference: Chidambaram Gunanathan, Yehoshoa Ben-David, David Milstein. 2007....

295 – Milstein catalyst

Description: Carbonylhydrido[6-(di-t-butyl-phosphinomethylene)-2-(N,N-diethylaminomethyl)-1,6-dihydropyridine]ruthenium(II).

Ruthenium-based catalyst that converts amines and alcohols into amides.

Reference: Chidambaram Gunanathan, Yehoshoa Ben-David, David Milstein. 2007. Direct Synthesis of Amides from Alcohols and Amines with Liberation of H2. Science

317(5839):790-2.

+
  • Prof. David Milstein
179
179 - Allyl-mercapto-captopril (CPSSA - Captosal) Description: Conjugation between allicin (the biologically active molecule in garlic) and captopril, a known antihypertensive drug. Was shown to offer therapeutic benefits for the treatment of the metabolic syndrome, as demonstrated by various animal...

179 - Allyl-mercapto-captopril (CPSSA - Captosal)

Description: Conjugation between allicin (the biologically active molecule in garlic) and captopril, a known antihypertensive drug. Was shown to offer therapeutic benefits for the treatment of the metabolic syndrome, as demonstrated by various animal models. These include improvement of glucose tolerance, preventing weight gain, lowering blood pressure, reducing cardiac hypertrophy and potent antioxidant activities.

Reference: Miron T, Rabinkov A, Peleg E, Rosenthal T, Mirelman D, Wilcheck M. 2004. Allylmercaptocaptopril: a new antihypertensive drug. Am. J. Hypertens. 1:71-73.

+
  • Prof. David Mirelman
265
Monoclonal antibodies specific to cholesterol/ceramide mixture Description: Monoclonal antibodies specific for cholesterol/ceramide-rich domains (clones 405F, 14F, 499F) and cholesterol micro-domains (clones 36A1, 5881) in cell membranes. Originally raised against an artificial monolayer of lipid...

Monoclonal antibodies specific to cholesterol/ceramide mixture

Description: Monoclonal antibodies specific for cholesterol/ceramide-rich domains (clones 405F, 14F, 499F) and cholesterol micro-domains (clones 36A1, 5881) in cell membranes.

Originally raised against an artificial monolayer of lipid mixtures in, and were shown to specifically label the above domains in different cell membranes.

Reference:  Scheffer L, Futerman AH, Addadi L. 2007. Antibody labeling of cholesterol/ceramide ordered domains in cell membranes. Chembiochem 8(18):2286-94.

+
  • Prof. Lia Addadi
120
Monoclonal antibodies raised against bFSH. Available clone: 1G12. Follicle-stimulating hormone (FSH) is synthesized and secreted by gonadotrophs of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation and reproductive processes of the body.Reference: Somjen D1,...

Monoclonal antibodies raised against bFSH. Available clone: 1G12.
Follicle-stimulating hormone (FSH) is synthesized and secreted by gonadotrophs of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation and reproductive processes of the body.
Reference: Somjen D1, Tordjman K, Kohen F, Baz M, Razon N, Ouaknine G, Stern N. 1997. Combined beta FSH and beta LH response to TRH in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf). 46(5):555-62.

Monoclonal antibodies for peptide and steroid hormones

Due to their high specificity and sensitivity these antibodies may be applicable for research, diagnosis and therapeutics. A particular use may be quality control of industrial manufacturing of food products.

 

Peptide Hormones:

§  120 – Monoclonal antibody to FSH

Description: Monoclonal antibodies raised against bFSH. Available clone: 1G12.

Follicle-stimulating hormone (FSH) is synthesized and secreted by gonadotrophs of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation and reproductive processes of the body.

      Reference: Somjen D1, Tordjman K, Kohen F, Baz M, Razon N, Ouaknine G, Stern N. 1997. Combined beta FSH and beta LH response to TRH in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf). 46(5):555-62.


 

+
  • Dr. Fortune Kohen
147
Monoclonal antibodies raised against bhCG. Available clones: 1D5 (IgG1), 1E11 (IgG2b).Human chorionic gonadotropin (hCG) is a hormone produced by the syncytiotrophoblast, a component of the fertilized egg, after conception. Monoclonal antibodies for peptide and steroid hormones Due to their high...

Monoclonal antibodies raised against bhCG. Available clones: 1D5 (IgG1), 1E11 (IgG2b).
Human chorionic gonadotropin (hCG) is a hormone produced by the syncytiotrophoblast, a component of the fertilized egg, after conception.

Monoclonal antibodies for peptide and steroid hormones

Due to their high specificity and sensitivity these antibodies may be applicable for research, diagnosis and therapeutics. A particular use may be quality control of industrial manufacturing of food products.

Peptide Hormones:

§  147-148 - Monoclonal antibody to hCG

Description: Monoclonal antibodies raised against bhCG. Available clones: 1D5 (IgG1), 1E11 (IgG2b).

Human chorionic gonadotropin (hCG) is a hormone produced by the syncytiotrophoblast, a component of the fertilized egg, after conception.

 
+
  • Dr. Fortune Kohen
252
Due to their high specificity and sensitivity these antibodies may be applicable for research, diagnosis and therapeutics. A particular use may be quality control of industrial manufacturing of food products. Anti-idiotypic antibody raised against anti-progesterone-7- BSA.KLH conjugate (clone 2H4)....

Due to their high specificity and sensitivity these antibodies may be applicable for research, diagnosis and therapeutics. A particular use may be quality control of industrial manufacturing of food products.
Anti-idiotypic antibody raised against anti-progesterone-7- BSA.KLH conjugate (clone 2H4). Available clones: 15F11 (betatypic), 2E11  (alphatypic).
Reference: Fort?ne Kohen, Josef de Boever, Geoff Barnard. 1996.  Noncompetitive immunoassay for small molecules. Immunoassay. Pages  405-421.

Monoclonal antibodies for peptide and steroid hormones

Due to their high specificity and sensitivity these antibodies may be applicable for research, diagnosis and therapeutics. A particular use may be quality control of industrial manufacturing of food products.

Anti-idiotypic antibodies to anti-steroids:

§  252-253 - Anti-idiotypic antibodies against anti-progesterone   

      Description: Anti-idiotypic antibody raised against anti-progesterone-7-     BSA.KLH conjugate (clone 2H4). Available clones: 15F11 (betatypic), 2E11 (alphatypic).

            Reference: Fort?ne Kohen, Josef de Boever, Geoff Barnard. 1996. Noncompetitive immunoassay for small molecules. Immunoassay. Pages 405-421.

 
+
  • Dr. Fortune Kohen
101
Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry. Leukotrienes: §  101 – Monoclonal antibody to LTC4 Description: Rat monoclonal antibodies raised...

Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs

May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry.

Leukotrienes:

§  101 – Monoclonal antibody to LTC4

Description: Rat monoclonal antibodies raised against Leukotriene C4-KLH.

Available clone:  6E7 (IgG1).

Cysteinyl leukotrienes are potent lipid mediators in inflammation, inducing

smooth muscle contractions and increased capillary permeability.

 
+
  • Dr. Fortune Kohen
315
315 - TBBL (5-thiobutyl butyrolactone) Description: TBBL (5-thiobutyl butyrolactone) is a chromogenic lipo-lactone substrate for Serum paraoxonases (PONs), used for sera tests of PONs activity, based on their lactonase activity.  The primary enzymatic reaction produces an unstable intermediate that...

315 - TBBL (5-thiobutyl butyrolactone)

Description: TBBL (5-thiobutyl butyrolactone) is a chromogenic lipo-lactone substrate for Serum paraoxonases (PONs), used for sera tests of PONs activity, based on their lactonase activity.  The primary enzymatic reaction produces an unstable intermediate that rapidly collapses to release a fluorescent/chromogenic moiety.

Can be used with a variety of biological samples, for example, serum, cells or cell lysates and suitable for high-throughput screens.

Serum paraoxonase (PON1) is a high-density lipoprotein(HDL)-associated enzyme with antiatherogenic and detoxification properties that hydrolyzes a wide range of substrates and exhibits a wide range of physiologically important activities, including cholesterol efflux, drug metabolism and the detoxification of Ops (organophosphates).

Reference: Khersonsky O, Tawfik DS. 2006. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chembiochem. 7(1):49-53.

+
  • Prof. Dan S. Tawfik
1655
Cellular senescence is a permanent cell cycle arrest induced by damage or stress applied on proliferating cells. In a cell autonomous manner, senescence is a potent barrier to tumorgenesis and contributes to the cytotoxicity of some anti-cancer drugs. However, with age senescence cells accumulate and...

Cellular senescence is a permanent cell cycle arrest induced by damage or stress applied on proliferating cells. In a cell autonomous manner, senescence is a potent barrier to tumorgenesis and contributes to the cytotoxicity of some anti-cancer drugs. However, with age senescence cells accumulate and promote a number of pathological conditions. Therefore the elimination of senescent cells is desired in order to prevent tumor- and inflammation- related pathologies and also to inhibit tissue ageing.
Today, our understanding of the mechanisms regulating the viability of senescent cells is limited. It has been suggested that senescent cells are resistant to apoptosis. Therefore, senescent cells elimination may be achieved by modifying the resistance to apoptosis of these cells.
Here the researches demonstrate the first feasible therapeutic approach that leads to eradication of senescent cells. Combination of direct induction of apoptosis in senescent cells with induction of cell death by pro-inflammatory repose induce by p21 knockdown will lead to reduction of viable senescent cells.

Applications


  • A therapeutic impact on inflammatory and fibrotic disease
  • Therapy for age-related disease such as type 2 diabetes, Alzheimer’s disease, Atherosclerosis, cataracts, Chronic obstructive pulmonary disease (COPD), and Osteoporosis

Advantages


  • Effective elimination of senescent cells- removal of senescent cells can prevent or delay tissue dysfunction and extend health span
  • Does not damage normal cells even at high concentrations

Technology's Essence


Researches demonstrated that the anti-apoptotic proteins Bcl-xL and Bcl-w level were elevated in senescence cells of both human and mouse origin. A subsequent study, in which Bcl-xL and Bcl-w were knocked down by siRNA, revealed that a combined knock down of Bcl-xL and Bcl-w had synergic effect, resulting in reduction of 50% in cell viability. Thus the increased level of anti-apoptotic proteins Bcl-xL and Bcl-w may account for the apoptotic resistance of senescent cells. p21 knockdown induced pro-inflammatory response and cell death in senescent cells.
Overall, the researchers show that combined inhibition of the anti-apoptotic proteins Bcl-xL and Bcl-w allows specific elimination of senescent cells and might be used to treat diseases where senescent cells are present. The researchers also found that the same effect might be achieved by reducing the expression of p21 in senescent cells. Integrating both approaches propose a more effective therapy.

+
  • Ph.D. Valery Krizhanovsky
1698
GD is an inherited metabolic disorder, affecting about 1 in 20,000 births. GD is divided into three clinical subtypes: type 1 is the most common and is characterized by bruising, fatigue, anemia, low blood platelets, and enlargement of the liver and spleen. Types 2 and 3, also called neuronopathic GD (...

GD is an inherited metabolic disorder, affecting about 1 in 20,000 births. GD is divided into three clinical subtypes: type 1 is the most common and is characterized by bruising, fatigue, anemia, low blood platelets, and enlargement of the liver and spleen. Types 2 and 3, also called neuronopathic GD (nGD), affect 4% of GD patients and additionally include neurological symptoms. Type 1 patients can have a normal life expectancy if treated whereas type 2/3 patients do not survive to reach adulthood. Moreover, GD carriers, approximately 1% of the population, are in a major risk of developing Parkinson’s disease. Current therapies suffer from severe drawbacks in the treatment of type 1 GD and no therapy exists that effectively treat nGD. The present technology offers a novel therapeutic target for the treatment of Gaucher's disease (GD) which addresses also the neurological symptoms.

Applications


  • Alternative treatment for type 1 GD
  • First line therapy for nGD

Advantages


  • A novel therapy for nGD which has no treatment for the present.
  • A novel therapeutic approach for GD type 1, via a previously unknown molecular mechanism.
  • Allows the development of an orally administered treatment, far more convenient for the patients than the existing treatments.
  • Reduced costs compared to the existing therapies of ERP or BMT

Technology's Essence


The proposed technology is based on the discovery that RIP3 is a key player in the manifestation of GD and that inhibiting RIP3 activity is effectively ameliorating the symptoms of GD not only in the less severe type 1 but also in the neuropathic form of the disease, types 2 and 3. nGD is associated with a massive neuronal loss and elevated RIP3 levels. Inhibition of RIP3 in a mouse model of nGD resulted in a dramatic attenuation of disease signs: drastic extension of life span, no weight loss, improvements in motor coordination, reduced neuroinflammation and improved liver and spleen injuries.

+
  • Prof. Anthony H. Futerman

Pages